Citadel Advisors’s ASP Isotopes ASPI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.12M Sell
1,159,500
-1,057,400
-48% -$6.25M ﹤0.01% 4292
2025
Q4
$11.9M Buy
2,216,900
+882,900
+66% +$7.02M ﹤0.01% 3035
2025
Q3
$12.8M Buy
1,334,000
+1,224,700
+1,120% +$11.3M ﹤0.01% 2901
2025
Q2
$804K Sell
109,300
-238,100
-69% -$1.6M ﹤0.01% 7559
2025
Q1
$1.63M Buy
347,400
+243,900
+236% +$1.22M ﹤0.01% 5928
2024
Q4
$469K Buy
+103,500
New +$551K ﹤0.01% 8695

Other funds holding ASPI

Citadel Advisors's ASPI Position: Q1 2026 in Review

Citadel Advisors reduced its ASP Isotopes (ASPI) stake by 55% in Q1 2026, selling an estimated $5.66M and leaving 768,006 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #5017.

Citadel Advisors first reported a position in ASPI in Q4 2023 and has held it in 6 quarters since. The position peaked at $11.2M in Q3 2025. 177 funds tracked by Wall St. Rank hold ASPI as of Q1 2026.

  • Citadel Advisors held 768,006 shares of ASP Isotopes worth $3.39M as of Q1 2026.
  • Citadel Advisors sold 957,547 ASP Isotopes shares in Q1 2026, an estimated $5.66M.
  • ASP Isotopes made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5017 holding.
  • Citadel Advisors first reported a position in ASP Isotopes in Q4 2023 and has held it in 6 quarters since.
  • Citadel Advisors's ASP Isotopes position peaked at $11.2M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held ASP Isotopes as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.